Send to

Choose Destination
Ann Neurol. 2020 Mar;87(3):329-338. doi: 10.1002/ana.25682. Epub 2020 Feb 5.

Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging.

Author information

Positron Emission Tomography Research Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT.
Department of Psychiatry, Yale University, New Haven, CT.
Department of Neurology, Yale University, New Haven, CT.
Translational Imaging, Integrated Science and Technology, AbbVie, North Chicago, IL.



Parkinson disease is characterized by motor and nonmotor symptoms, reduced striatal dopamine signaling, and loss of dopamine neurons in the substantia nigra. It is now known that the pathological process in Parkinson disease may begin decades before the clinical diagnosis and include a variety of neuronal alterations in addition to the dopamine system.


This study examined the density of all synapses with synaptic vesicle glycoprotein 2A (SV2A) in Parkinson disease subjects with mild bilateral disease (n = 12) and matched normal controls (n = 12) using in vivo high-resolution positron emission tomographic imaging as well as postmortem autoradiography in an independent sample with Parkinson disease (n = 15) and normal controls (n = 13) in the substantia nigra and putamen.


A group-by-brain region interaction effect (F10, 22 = 3.52, p = 0.007) was observed in the primary brain areas with in vivo SV2A binding. Post hoc analyses revealed that the Parkinson disease group exhibited lower SV2A in the substantia nigra (-45%; p < 0.001), red nucleus (-31%; p = 0.03), and locus coeruleus (-17%; p = 0.03). Exploratory analyses also revealed lower SV2A binding in clinically relevant cortical areas. Using autoradiography, we confirmed lower SV2A in the substantia nigra (-17%; p < 0.005) and nonsignificant findings in the putamen (-4%; p = 0.06).


This work provides the first evidence of synaptic loss in brainstem nuclei involved in the pathogenesis of Parkinson disease in living patients. SV2A imaging holds promise for understanding synaptic changes central to the disease. Ann Neurol 2020;87:329-338.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center